文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

CAR-T时代异基因造血细胞移植角色的演变

The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.
PubMed 文献 · Br J Haematol · 2021-04-29

本文综述了CAR-T疗法在复发难治高级别B细胞非霍奇金淋巴瘤和急性淋巴细胞白血病中取得显著疗效后,异基因造血细胞移植(allo-HCT)作为巩固策略的角色变化。文章指出B-ALL患者CAR-T后复发常见,高危患者allo-HCT可能改善生存,而B-NHL完全缓解后可能无需allo-HCT巩固,并提供了患者选择和实践指导。

要点

  • B-ALL患者CD19 CAR-T后复发频繁,高危患者可考虑allo-HCT巩固以改善生存。
  • B-NHL患者CAR-T后晚期复发少见,达完全缓解者可能无需allo-HCT巩固。
  • 成人B-ALL患者CAR-T后复发风险远高于儿童患者。

核心结论

  • CAR-T疗法革新了多种血液恶性肿瘤的治疗,allo-HCT的巩固角色需根据疾病类型和风险重新评估。
  • B-ALL高危患者CAR-T后allo-HCT可能改善生存,B-NHL完全缓解患者可能无需allo-HCT。

研究设计与样本

  • 本文为综述,基于现有文献汇总CAR-T时代allo-HCT的角色演变。

主要发现

  • CD19 CAR-T在复发难治高级别B-NHL和B-ALL中产生显著疾病缓解,部分患者持久缓解。
  • B-ALL患者CAR-T后复发频繁,成人复发风险远高于儿童。
  • B-NHL患者CAR-T后晚期复发少见,完全缓解者可能无需allo-HCT巩固。

关键数值与推荐

  • B-ALL高危患者可考虑allo-HCT巩固以改善生存。
  • B-NHL患者CAR-T后达完全缓解可能无需allo-HCT巩固。

临床怎么用

  • 应根据疾病类型(B-ALL vs B-NHL)和风险分层选择CAR-T后是否行allo-HCT。
  • 成人B-ALL患者CAR-T后需更密切监测复发并考虑allo-HCT巩固。

局限性

  • 需未来基于登记处和前瞻性研究数据以对CAR-T受者进行风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimaeric antigen receptor T-cell (CAR T) therapy has revolutionized the management of many haematological malignancies. It is associated with impressive disease responses in relapsed or refractory high-grade B-cell non-Hodgkin lymphoma (B-NHL) and acute lymphoblastic leukaemia (B-ALL) with durable remissions in a subset of patients. Historically, haematopoietic cell transplantation (HCT) has been the standard consolidation strategy for many of these patients who are now being treated with CAR T. Relapses are frequent after CD19 CAR T therapy in B-ALL and consolidation with allogeneic HCT (allo-HCT) may improve survival of patients with high-risk disease. There appears to be a clear difference in B-ALL outcomes between paediatric and adult patients, with the latter having a much higher risk of relapse after CAR T therapy. Late relapses are infrequent in patients with B-NHL and consolidation with allo-HCT may not be needed in patients who achieve a complete remission after CAR T therapy. Future registry-based and prospective studies will hopefully provide the needed data in the future to risk-stratify the recipients of CAR T therapy. Meanwhile, we provide guidance on patient selection and practical issues with performing allo-HCT after CAR T therapy.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dholaria B, Savani BN, Huang XJ, et al. The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy. Br J Haematol. 2021. PMID: 33928630. doi:10.1111/bjh.17460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。